Wouter W. de Herder

37.9k total citations · 9 hit papers
411 papers, 24.0k citations indexed

About

Wouter W. de Herder is a scholar working on Epidemiology, Oncology and Neurology. According to data from OpenAlex, Wouter W. de Herder has authored 411 papers receiving a total of 24.0k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Epidemiology, 181 papers in Oncology and 178 papers in Neurology. Recurrent topics in Wouter W. de Herder's work include Neuroendocrine Tumor Research Advances (250 papers), Neuroblastoma Research and Treatments (167 papers) and Lung Cancer Research Studies (148 papers). Wouter W. de Herder is often cited by papers focused on Neuroendocrine Tumor Research Advances (250 papers), Neuroblastoma Research and Treatments (167 papers) and Lung Cancer Research Studies (148 papers). Wouter W. de Herder collaborates with scholars based in Netherlands, Italy and Germany. Wouter W. de Herder's co-authors include Richard A. Feelders, Dik J. Kwekkeboom, Steven W. J. Lamberts, Eric P. Krenning, Leo J. Hofland, Casper H.J. van Eijck, Boen L.R. Kam, Jaap J.M. Teunissen, P.P.M. Kooij and Maarten O. van Aken and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Wouter W. de Herder

402 papers receiving 23.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gastroenteropancreatic neuroendocrine tumours

2008 1.2k citations Kjell Öberg, Wouter W. de Herder et al. profile →
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system

2006 1.2k citations Martyn Caplin, Wouter W. de Herder et al. profile →
Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

2008 1.1k citations Dik J. Kwekkeboom, Wouter W. de Herder et al. Journal of Clinical Oncology profile →
Octreotide

1996 752 citations Steven W. J. Lamberts, Wouter W. de Herder et al. profile →
Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

2005 517 citations Dik J. Kwekkeboom, Willem H. Bakker et al. Journal of Clinical Oncology profile →
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms

2022 486 citations Shereen Ezzat, Wouter W. de Herder et al. Endocrine Pathology profile →
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

2017 416 citations Tessa Brabander, Boen L.R. Kam et al. profile →
ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

2016 330 citations Dermot O’Toole, Diego Ferone et al. Neuroendocrinology profile →
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

2024 113 citations Marianne Pavel, Wouter W. de Herder et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wouter W. de Herder Netherlands	78	16.0k	13.0k	10.7k	6.9k	4.9k	411	24.0k
Kjell Öberg Sweden	78	20.6k 1.3×	18.2k 1.4×	14.5k 1.4×	2.0k 0.3×	2.3k 0.5×	402	26.1k
Eric P. Krenning Netherlands	83	14.5k 0.9×	12.5k 1.0×	9.4k 0.9×	2.8k 0.4×	1.6k 0.3×	277	22.6k
Aurel Perren Switzerland	62	9.8k 0.6×	9.3k 0.7×	5.9k 0.6×	2.0k 0.3×	3.1k 0.6×	259	15.6k
Philippe Ruszniewski France	78	15.5k 1.0×	17.6k 1.4×	9.5k 0.9×	819 0.1×	6.2k 1.3×	426	22.9k
Richard A. Feelders Netherlands	57	4.9k 0.3×	3.4k 0.3×	3.3k 0.3×	6.5k 1.0×	3.7k 0.8×	272	12.5k
Larry K. Kvols United States	63	10.2k 0.6×	9.2k 0.7×	7.3k 0.7×	1.0k 0.2×	1.5k 0.3×	225	13.8k
Henning Dralle Germany	73	6.1k 0.4×	4.7k 0.4×	2.4k 0.2×	15.9k 2.3×	13.8k 2.8×	585	26.8k
E. P. Krenning Netherlands	58	8.4k 0.5×	6.7k 0.5×	5.2k 0.5×	2.5k 0.4×	1.0k 0.2×	168	12.7k
Bruno Niederle Austria	56	4.3k 0.3×	4.1k 0.3×	2.1k 0.2×	4.3k 0.6×	4.1k 0.8×	327	11.6k
Casper H.J. van Eijck Netherlands	66	6.1k 0.4×	12.4k 1.0×	2.9k 0.3×	794 0.1×	7.4k 1.5×	420	17.6k

Countries citing papers authored by Wouter W. de Herder

Since Specialization

Citations

This map shows the geographic impact of Wouter W. de Herder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wouter W. de Herder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wouter W. de Herder more than expected).

Fields of papers citing papers by Wouter W. de Herder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wouter W. de Herder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wouter W. de Herder. The network helps show where Wouter W. de Herder may publish in the future.

Co-authorship network of co-authors of Wouter W. de Herder

This figure shows the co-authorship network connecting the top 25 collaborators of Wouter W. de Herder. A scholar is included among the top collaborators of Wouter W. de Herder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wouter W. de Herder. Wouter W. de Herder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mirzaian, Mina, et al.. (2025). Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome. The Journal of Clinical Endocrinology & Metabolism. 110(12). e3980–e3988.

Herder, Wouter W. de, et al.. (2023). What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators. Endocrine Reviews. 45(3). 351–360. 8 indexed citations

Herder, Wouter W. de & Günter Klöppel. (2023). One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones. Endocrine Related Cancer. 30(9). 1 indexed citations

Koetsveld, P. M. van, Richard A. Feelders, Leo J. Hofland, et al.. (2023). Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature. European Journal of Cancer. 197. 113472–113472. 4 indexed citations

Ezzat, Shereen, Wouter W. de Herder, Marco Volante, & Ashley Grossman. (2023). The Driver Role of Pathologists in Endocrine Oncology: What Clinicians Seek in Pathology Reports. Endocrine Pathology. 34(4). 437–454. 3 indexed citations

Merola, Elettra, Aurel Perren, Anja Rinke, et al.. (2022). High rate of Ki‐67 increase in entero‐pancreatic NET relapses after surgery with curative intent. Journal of Neuroendocrinology. 34(10). e13193–e13193. 9 indexed citations

Hofland, Johannes, Tessa Brabander, Frederik A. Verburg, Richard A. Feelders, & Wouter W. de Herder. (2022). Peptide Receptor Radionuclide Therapy. The Journal of Clinical Endocrinology & Metabolism. 107(12). 3199–3208. 24 indexed citations

Blažević, Anela, Anand M. Iyer, Marie‐Louise F. van Velthuysen, et al.. (2022). Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis ismall intestinal neuroendocrine tumors. EUR Research Repository (Erasmus University Rotterdam). 4 indexed citations

Blažević, Anela, Anand M. Iyer, Marie‐Louise F. van Velthuysen, et al.. (2022). Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women. The Journal of Clinical Endocrinology & Metabolism. 107(5). e1969–e1975. 13 indexed citations

10.

Dromain, Clarisse, Marie‐Pierre Vullierme, Rodney J. Hicks, et al.. (2021). ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Journal of Neuroendocrinology. 34(3). e13044–e13044. 13 indexed citations

11.

Hicks, Rodney J., Clarisse Dromain, Wouter W. de Herder, et al.. (2021). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology. 34(3). e13040–e13040. 13 indexed citations

12.

Zandee, Wouter T., Tessa Brabander, Anela Blažević, et al.. (2021). Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. The Journal of Clinical Endocrinology & Metabolism. 106(9). e3665–e3672. 40 indexed citations

13.

García‐Carbonero, Rocio, Anja Rinke, Juan W. Valle, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. Neuroendocrinology. 105(3). 281–294. 82 indexed citations

14.

Kaltsas, Gregory, Martyn Caplin, Philippa Davies, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 105(3). 245–254. 99 indexed citations

15.

Pavel, Marianne, Juan W. Valle, Barbro Eriksson, et al.. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 105(3). 266–280. 110 indexed citations

16.

Koetsveld, Peter M. van, Giovanni Vitale, Richard A. Feelders, et al.. (2013). Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocrine Related Cancer. 20(3). 443–454. 16 indexed citations

17.

Feelders, Richard A., Theo H.N. Groenland, Anton H. van den Meiracker, et al.. (2009). Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism. 95(2). 678–685. 171 indexed citations

18.

Kwekkeboom, Dik J., Wouter W. de Herder, Boen L.R. Kam, et al.. (2008). Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival. Journal of Clinical Oncology. 26(13). 2124–2130. 1093 indexed citations breakdown →

19.

Valkema, Roelf, Marion de Jong, Willem H. Bakker, et al.. (2002). Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience. Seminars in Nuclear Medicine. 32(2). 110–122. 328 indexed citations

20.

Bonjer, H. J., H. A. Bruining, Roelf Valkema, et al.. (1997). Single radionuclide scintigraphy with 99mTechnetium-Sestamibi and ultrasonography in hyperparathy-roidism.. EUR Research Repository (Erasmus University Rotterdam). 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact